AstraZeneca Group plc Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 16 of 119 Posts
1 2 3 ... 8
Week In Review: Walgreens Boots Alliance Spends $420 Million For China Pharmacy Presence
Article By: ChinaBio® Today Saturday, December 2, 2017 4:50 PM EST
Global retail pharmacy Walgreens Boots Alliance will pay $420 million to acquire a 40% stake in Sinopharm Holding GuoDa Drug Store Co, the largest retail pharmacy chain in China.
In this article: AZN, GSK, GILD, WBA
Pharma Stock Roundup: AstraZeneca's Q3 Earnings, Roche & Merck Drugs Get FDA Nod
Article By: Arpita Dutt Friday, November 10, 2017 3:13 PM EST
Earnings remained in focus this week with companies like AstraZeneca reporting third-quarter results. Meanwhile, companies like Roche and Merck & Co., Inc. were in the news due to regulatory updates.
In this article: AZN, GSK, MRK Also: JNJ, LLY, SNY, RHHBY
AstraZeneca (AZN) Misses Q3 Earnings, Tweaks 2017 EPS View
Article By: Zacks Investment Research Thursday, November 9, 2017 11:15 AM EST
AstraZeneca plc reported third-quarter 2017 core earnings of 56 cents per American Depositary Share (ADS), which missed the Zacks Consensus Estimate of 57 cents.
In this article: AZN Also: MRK, JNJ
Week In Review: WuXi AppTec Acquires US-Global Clinical CRO
Article By: ChinaBio® Today Saturday, October 21, 2017 5:25 PM EST
WuXi AppTec, China's largest CRO/CMO, will acquire a global clinical-stage contract research company, ResearchPoint Global, of Austin,Texas. WuXi said the acquisition would extend its CRO network around the world.
In this article: AZN, HCM, RVX, FGEN
AstraZeneca's Asthma Candidate Shows Promising Results
Article By: Zacks Investment Research Tuesday, September 12, 2017 12:33 PM EST
AstraZeneca Plc. announced a subgroup analysis from SIROCCO and CALIMA phase III studies. The studies revealed the efficacy of benralizumab and also showed that this antibody provides increased benefits to patients.
In this article: AZN Also: SNY, REGN
Astrazeneca, Amgen Phase IIb Trial Of Tezepelumab Met Primary Endpoint
Article By: The Fly Thursday, September 7, 2017 8:20 AM EST
AstraZeneca and Amgen announced results from the Pathway Phase IIb trial of tezepelumab that they say "showed a significant reduction" in the annual asthma exacerbation rate compared with placebo in patients with severe, uncontrolled asthma.
In this article: AZN, AMGN
AstraZeneca And Takeda Pharmaceutical Company Limited Parkinson's Collaboration
Article By: Samuel Rae Thursday, August 31, 2017 12:48 PM EST
AstraZeneca announced that it has put together a deal with Takeda Pharmaceutical Company Limited that will see the two collaborate on the development of a brand-new Parkinson's disease asset.
In this article: AZN, TKPYY Also: RHHBY, PRTA
AstraZeneca And Takeda Ink Deal To Develop Parkinson's Drug
Article By: Zacks Investment Research Wednesday, August 30, 2017 3:10 PM EST
AstraZeneca PLC and Takeda Pharmaceutical Company Limited, a Japanese pharma company, have entered into an agreement to jointly develop and commercialize preclinical candidate MEDI1341.
In this article: AZN Also: RHHBY, ACOR, PRTA
Citi Sees Advantage For Tesaro Despite Broad Lynparza Label
Article By: The Fly Friday, August 18, 2017 6:00 AM EST
Citi analyst Robyn Karnauskas says the "broad label" given yesterday to AstraZeneca's Lynparza increases competition for Tesaro.
In this article: AZN, TSRO Also: CLVS
AstraZeneca Plunges Following Failed Lung Cancer Study
Article By: The Fly Thursday, July 27, 2017 2:34 PM EST
Shares of AstraZeneca are dropping sharply after the company said its MYSTIC trial failed to show its two-drug combination extended progression-free survival compared with standard-of-care chemotherapy for lung cancer patients.
In this article: AZN Also: MRK, TEVA, BMY
AstraZeneca Says Phase III MYSTIC Trial Did Not Meet Primary Endpoint
Article By: The Fly Thursday, July 27, 2017 7:29 AM EST
The combination of Imfinzi and tremelimumab did not meet the primary endpoint of improving PFS compared to SoC in patients whose tumors express PD-L1 on 25% or more of their cancer cells.
In this article: AZN
Three Large Cap Pharma Stocks To Buy Now
Article By: Zacks Investment Research Wednesday, July 12, 2017 5:20 AM EST
While investors might think that the uncertainty of health care reform would bring volatility into the sector, we’ve actually seen healthcare stocks have a pretty decent year so far. The overall “Medical” sector is up about 11.9% year-to-date.
In this article: AZN, BAYRY, HLUYY
Hot Options Report: End Of Day - Monday, July 10
Article By: The Options Insider Monday, July 10, 2017 10:29 PM EST
Most active stock options for end of day Monday: BAC, ASH, X, CSX, ICE, AAPL, CBI, NVDA and AZN.
In this article: ASH, AZN, BAC, CBI, CSX, ICE, X, AAPL, NVDA
Week In Review: Sinovac's Privatization Offer Draws $459 Million Outside Bid
Article By: ChinaBio® Today Saturday, July 1, 2017 7:14 PM EST
Shandong Sinobioway Biomedicine topped management's $402 million bid to privatize China vaccine maker Sinovac with a $459 million offer of its own. Sinovac is a Beijing vaccine company with legacy vaccines for hepatitis A and B.
In this article: AZN, GE, SVA, HCM
AstraZeneca: 4% Dividend Yield And A Pipeline To Emerging Market Growth
Article By: SureDividend Thursday, June 15, 2017 11:35 AM EST
AstraZeneca’s strong pipeline and heavy presence in the emerging markets lay the groundwork for future growth.
In this article: AZN Also: JNJ, ABT
AstraZeneca Enters Agreement With Grunenthal To Divest Rights To Zomig
Article By: The Fly Wednesday, June 7, 2017 12:10 PM EST
AstraZeneca announced that it has entered an agreement with Grunenthal for the global rights to Zomig outside Japan.
In this article: AZN, IPXL
1 to 16 of 119 Posts
1 2 3 ... 8